Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.
Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.